Suraj Mudichintala

Early stage investing in deep tech / health.

• Bio IT  Pathology, neural circuitry, precision
• Augmentation  Expanding physical and mental capability
• Infrastructure  Physical AI and connected devices in health
• Value chain intelligence  Eliminating healthcare deadweight loss

• 2025
  Synapse Fund

  Suraj manages investments in SR One’s “Synapse Fund” as an appointed investment committee member, and serves on the boards of Alpheus Medical, Cala Health, Neuspera Medical, SetPoint Medical, and MicroTransponder. Suraj previously represented GSK on these boards, as well as the boards of Onc.AI and Axon Therapies.

• 2026

  Tacit.ai/Throne Science